Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response / Beltran, H., Eng, K., Mosquera, J.m., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., Park, K., Banfelder, J., Prandi, D., Madhukar, N., Zhang, T., Padilla, J., Greco, N., Mcnary, T.j., Herrscher, E., Wilkes, D., et al.. - In: JAMA ONCOLOGY. - ISSN 2374-2437. - 1:4(2015), p. 466-74. [10.1001/jamaoncol.2015.1313]
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Romanel, Alessandro;Prandi, Davide;Demichelis, Francesca;
2015-01-01
Abstract
Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer.| File | Dimensione | Formato | |
|---|---|---|---|
|
Demichelis-Whole-coi150029.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
750.68 kB
Formato
Adobe PDF
|
750.68 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
